Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Metagenomi, Inc. Common Stock (MGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: MGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.53% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.71M USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.23 - 4.92 | Updated Date 12/1/2025 |
52 Weeks Range 1.23 - 4.92 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.8 | Actual -0.55 |
Profitability
Profit Margin -287.06% | Operating Margin (TTM) -263.76% |
Management Effectiveness
Return on Assets (TTM) -19.02% | Return on Equity (TTM) -40.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -76744186 | Price to Sales(TTM) 2.13 |
Enterprise Value -76744186 | Price to Sales(TTM) 2.13 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37546751 | Shares Floating 27049055 |
Shares Outstanding 37546751 | Shares Floating 27049055 | ||
Percent Insiders 28.09 | Percent Institutions 17.9 |
Upturn AI SWOT
Metagenomi, Inc. Common Stock
Company Overview
History and Background
Metagenomi, Inc. is a biopharmaceutical company focused on discovering and developing novel, potentially curative gene editing therapies. The company was founded in 2018. It leverages metagenomics to identify and engineer novel CRISPR-associated (Cas) systems.
Core Business Areas
- Gene Editing Therapies: Focuses on developing gene editing therapies for various diseases using novel CRISPR systems identified through metagenomics.
- Metagenomics Platform: Utilizes a proprietary metagenomics platform to discover and engineer new gene editing tools and technologies.
Leadership and Structure
Brian C. Thomas is the CEO of Metagenomi. The company has a board of directors and a management team overseeing research, development, and business operations.
Top Products and Market Share
Key Offerings
- mgEDIT: A versatile gene editing platform derived from environmental microbes, offering improved specificity and efficiency. It is still in preclinical development. Competitors include CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (EDIT).
- Novel Cas Enzymes: Discovering and engineering new Cas enzymes with unique properties for gene editing. Currently being researched and developed for various therapeutic applications.Competitors include CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (EDIT).
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR technology and the potential to treat a wide range of genetic diseases. The space is competitive and quickly changing.
Positioning
Metagenomi is positioned as an innovator in gene editing, leveraging its metagenomics platform to discover novel CRISPR systems with potentially improved safety and efficacy profiles compared to existing technologies.
Total Addressable Market (TAM)
The total addressable market for gene editing therapies is estimated to be tens of billions of dollars. Metagenomi is positioned to capture a portion of this market with its novel gene editing platforms. It is estimated to reach $11.7 billion by 2027.
Upturn SWOT Analysis
Strengths
- Proprietary metagenomics platform
- Novel CRISPR systems with unique properties
- Experienced management team
- Strong intellectual property position
Weaknesses
- Early-stage company with no approved products
- Dependence on research and development success
- High cash burn rate
- Competition from established gene editing companies
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Advancement of lead programs into clinical trials
- Potential for breakthrough therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene editing technologies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRSP
- NTLA
- EDIT
Competitive Landscape
Metagenomi's competitive advantage lies in its novel CRISPR systems discovered through its metagenomics platform. However, it faces significant competition from larger, more established gene editing companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Metagenomi went public in Feb 2024. It's difficult to determine the historical growth without available and older public financial information.
Future Projections: Future growth is dependent on advancing its gene editing programs through clinical trials and securing partnerships. Analyst estimates for revenue growth vary widely.
Recent Initiatives: Focus on advancing its lead gene editing programs into clinical trials, expanding its metagenomics platform, and forging strategic partnerships.
Summary
Metagenomi is a promising early-stage gene editing company with a unique metagenomics platform. Its novel CRISPR systems offer potential advantages over existing technologies. However, the company faces significant risks related to clinical trial success, regulatory approvals, and competition. Its early stage makes it a very risky but possibly high reward investment.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metagenomi, Inc. Common Stock
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2024-02-09 | CEO, President, COO & Director Dr. Jian Irish M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 124 | Website https://metagenomi.co |
Full time employees 124 | Website https://metagenomi.co | ||
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.